View Older Stories View More Recent Stories

Aug 8, 2023 04:05PM Veracyte Announces Second Quarter 2023 Financial Results
Aug 1, 2023 08:15AM Veracyte (VCYT) Reports Study Showing Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
Aug 1, 2023 08:15AM Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
Jul 19, 2023 05:00PM Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
Jun 20, 2023 08:31AM New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
Jun 12, 2023 08:31AM Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
May 25, 2023 05:13PM New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
May 24, 2023 09:00AM New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
May 23, 2023 05:00PM Veracyte to Participate in Upcoming Investor Conferences
May 12, 2023 06:15AM Veracyte (VCYT) Announces New Data Showing Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
May 12, 2023 06:15AM Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
May 4, 2023 04:05PM Veracyte Announces First Quarter 2023 Financial Results
May 4, 2023 09:45AM New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
May 3, 2023 05:44PM New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
May 2, 2023 04:06PM Veracyte (VCYT) Reports Publication Validating Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
May 2, 2023 04:05PM Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
May 1, 2023 05:35PM Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
Apr 29, 2023 04:31PM Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
Apr 27, 2023 04:05PM Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
Apr 17, 2023 08:30AM New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
Apr 13, 2023 05:00PM Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
Apr 12, 2023 08:30AM Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
Mar 15, 2023 04:15PM Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
Mar 13, 2023 05:51AM Veracyte (VCYT) Statement on Impact of Silicon Valley Bank
Mar 11, 2023 12:11PM Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
Feb 27, 2023 05:00PM Veracyte to Participate in Upcoming Investor Conferences
Feb 22, 2023 04:05PM Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
Feb 15, 2023 08:38AM Veracyte (VCYT) Says Data Published in "The Red Journal" Validate Prognostic Value of Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
Feb 15, 2023 08:36AM Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
Feb 13, 2023 05:23PM New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
Feb 6, 2023 05:00PM Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
Feb 1, 2023 04:05PM Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
Feb 1, 2023 08:33AM Veracyte (VCYT) Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
Feb 1, 2023 08:32AM Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
Jan 23, 2023 09:00AM Exagen Inc (XGN) Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
Jan 23, 2023 09:00AM Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
Jan 23, 2023 09:00AM Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
Dec 15, 2022 04:05PM Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
Nov 2, 2022 04:05PM Veracyte Announces Third Quarter 2022 Financial Results
Nov 1, 2022 05:11PM Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
Oct 27, 2022 05:00PM Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
Oct 25, 2022 08:30AM New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
Oct 24, 2022 08:30AM Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
Oct 18, 2022 04:05PM New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
Oct 13, 2022 05:00PM Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
Sep 22, 2022 08:56AM Veracyte (VCYT) Announces New Data Published in JNCI Demonstrate its Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
Sep 22, 2022 08:55AM New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
Sep 13, 2022 08:30AM Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
Sep 12, 2022 05:43AM Veracyte (VCYT) Reports Strong Phase 3 Data of Decipher Prostate Genomic Classifier
Sep 11, 2022 02:30AM New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
View More Recent Stories View Older Stories